VIA
DNLI icon

Virtus Investment Advisers’s Denali Therapeutics DNLI Stock Holding History

Virtus Investment Advisers’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$291K Buy
15,166
+371
+3% +$7.38K 0.08% 283
2025
Q4 		$244K Buy
14,795
+7,171
+94% +$121K 0.07% 340
2025
Q3 		$111K Buy
7,624
+1,324
+21% +$19K 0.03% 412
2025
Q2 		$88.1K Sell
6,300
-691
-10% -$9.73K 0.03% 391
2025
Q1 		$95K Buy
+6,991
New +$134K 0.03% 428

Other funds holding DNLI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Virtus Investment Advisers's DNLI Position: Q1 2026 in Review

Virtus Investment Advisers increased its Denali Therapeutics (DNLI) stake by 2.5% in Q1 2026, buying an estimated $7.38K and bringing the position to 15,166 shares worth $291K. The position accounts for 0.08% of the portfolio, ranked #283.

Virtus Investment Advisers first reported a position in DNLI in Q1 2025 and has held it in 5 quarters since. 268 funds tracked by Wall St. Rank hold DNLI as of Q1 2026.

  • Virtus Investment Advisers held 15,166 shares of Denali Therapeutics worth $291K as of Q1 2026.
  • Virtus Investment Advisers bought 371 Denali Therapeutics shares in Q1 2026, an estimated $7.38K.
  • Denali Therapeutics made up 0.08% of Virtus Investment Advisers's portfolio in Q1 2026, its #283 holding.
  • Virtus Investment Advisers first reported a position in Denali Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • 268 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2026.

Based on Virtus Investment Advisers's 13F filing for Q1 2026, filed 14 May 2026.